Lentiglobin

Gene Therapy LentiGlobin Granted Priority Medicines Designation for Sickle Cell Disease in the EU
Actualités

Gene Therapy LentiGlobin Granted Priority Medicines Designation for Sickle Cell Disease in the EU

Bluebird Bio’s investigational gene therapy LentiGlobin has been granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of sickle cell disease (SCD). Given to candidate therapies with promising clinical data for diseases of high…
Bouton retour en haut de la page